Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia? ; volume:38 ; number:11 ; day:10 ; month:9 ; year:2024 ; pages:2376-2381 ; date:11.2024
Leukemia ; 38, Heft 11 (10.9.2024), 2376-2381, 11.2024

Creator: Stutterheim, Janine
Waarden, Rachella van der
Groot-Kruseman, Hester A. de
Sonneveld, Edwin
Haas, Valérie de
Dandis, Rana
Schoot, C. Ellen van der
Velden, Vincent H. J. van der
Pieters, Rob

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41375-024-02386-5

URN: urn:nbn:de:101:1-2501172105133.920873178186

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:31 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Stutterheim, Janine
Waarden, Rachella van der
Groot-Kruseman, Hester A. de
Sonneveld, Edwin
Haas, Valérie de
Dandis, Rana
Schoot, C. Ellen van der
Velden, Vincent H. J. van der
Pieters, Rob
SpringerLink (Online service)

Other Objects (12)

Measurable residual disease

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions

How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia

Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing

Have we been qualifying measurable residual disease correctly?

Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease (MRD)-testing in haematological and solid cancers

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Measurable residual disease

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions

How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia

Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing

Have we been qualifying measurable residual disease correctly?

Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease (MRD)-testing in haematological and solid cancers

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Measurable residual disease

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions

How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia

Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing

Have we been qualifying measurable residual disease correctly?

Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease (MRD)-testing in haematological and solid cancers

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Measurable residual disease

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions

How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia

Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing

Have we been qualifying measurable residual disease correctly?

Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease (MRD)-testing in haematological and solid cancers

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Measurable residual disease

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions

How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia

Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing

Have we been qualifying measurable residual disease correctly?

Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease (MRD)-testing in haematological and solid cancers

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Measurable residual disease

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions

How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia

Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing

Have we been qualifying measurable residual disease correctly?

Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease (MRD)-testing in haematological and solid cancers

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Related objects

Reset password